Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2021. The document serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific securities transaction.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction involving the acquisition of American Depositary Shares (ADSs) by Dr. H Barron, Chief Scientific Officer and President, R&D.
Transaction Details
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053
- Transaction Type: Acquisition within the GSK Executive Supplemental Savings Plan account
- Price: $36.0600 per ADS
- Volume: 1,284.072 ADSs
- Date: April 7, 2021
- Exchange: New York Stock Exchange (XNYS)
Investor Verification Points
- Verify the total number of ADSs held by Dr. H Barron post-transaction to assess insider ownership levels.
- Confirm the terms of the GSK Executive Supplemental Savings Plan to understand the nature of the acquisition.
- Review the company's Form 20-F for comprehensive financial results, as this 6-K contains no financial statements.